To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Inclusion Criteria:

• Patients who have given informed consent in accordance with the methods and procedures of this study
• Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
• Patients who have not received treatment related to his/her cancer
• Patients who are willing to sign a release of medical records to the research team
• Male and female patients ≥18 years of age
• Patients under oncology care of a participating site
• Sufficient clinical status for collection of biospecimen samples within usual care
• Patients who have insurance coverage for CMT

Exclusion Criteria:

• Patients considered minors in the jurisdiction where the protocol is conducted.
• Patients who are prisoners and pregnant women.
• Patients who cannot provide consent and did not sign a power of attorney.

Newly diagnosed cancer patients at the pathology level.